tumor treatment experiments. Groups of C57BL/6 mice were subcutaneously challenged with 3 × 104 TC-1 tumor cells per mouse on day 0. On day 5, the tumor-bearing mice were randomly divided into four groups (5 per group) and treated with one of the following regimens: vehicle, bortezomib alone (1 mg/kg, once every 3 days), SAHA alone (30 mg/kg, once per day), or the combination of bortezomib and SAHA. Bortezomib and SAHA were injected intraperitoneally and the treatment lasted for a total of 10 days. A. Schematic diagram of the treatment regimens. B. Line graph depicting the tumor volume in TC-1 tumor-bearing mice treated with bortezomib and/or SAHA (mean + SE; p < 0.05).